Cancer Prevalence in MSH3 Heterozygotes

Presenting Author: Kevin Beezhold, PhD

Take home points: 

1. In response to internal and external concerns about phenotype in heterozygous MSH3 pathogenic variant carriers, we reviewed our large internal cohort for any cancer predisposition.
2. Our study expands on previous reports and understanding that there is no risk for common cancers in heterozygous carriers.